Haemonetics Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Haemonetics de 21.1% y 6.8% por año respectivamente. Se prevé que el BPA crezca en un 19.8% al año. Se espera que la rentabilidad financiera sea de 19.1% en 3 años.

Información clave

21.6%

Tasa de crecimiento de los beneficios

19.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.3%
Tasa de crecimiento de los ingresos	6.8%
Rentabilidad financiera futura	19.1%
Cobertura de analistas	Good
Última actualización	02 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?

Apr 30

Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion

Apr 12

Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate

Mar 07

Haemonetics Corporation: Improved Performance, Another Bolt-On Deal

Mar 06

The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

Feb 15

Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment

Oct 13

Haemonetics' Fiscal Q1 2024: Blood, Sweat, And Stellar Gains

Aug 09

Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors

Aug 09

An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued

Jul 25

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Jul 07

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Apr 06

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?

Mar 19

Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer

Feb 16

Haemonetics: Earnings Rate Of Change Justifies High Multiples

Feb 01

We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Jan 05

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?

Dec 15

Haemonetics Q2 2023 Earnings Preview

Nov 04

Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

Oct 04

Haemonetics: Plasma Thesis Continues To Play Out, Reiterate Buy

Sep 06

Haemonetics reaches new 52-week high; shares up 41% YTD

Aug 24

Haemonetics reports Q2 earnings beat; raises FY22 guidance

Aug 10

A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Aug 10

Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly

Jul 03

Haemonetics: Upside Case Hinges On Blood Plasma Collection Market

Jun 11

Calculating The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

May 11

Is Haemonetics (NYSE:HAE) Using Too Much Debt?

Apr 01

Calculating The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Jan 28

Is Haemonetics (NYSE:HAE) Using Too Much Debt?

Dec 20

Is Haemonetics Corporation (NYSE:HAE) Worth US$68.5 Based On Its Intrinsic Value?

Oct 28

Haemonetics (NYSE:HAE) Is Doing The Right Things To Multiply Its Share Price

Oct 09

Previsiones de crecimiento de beneficios e ingresos

NYSE:HAE - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2027	1,594	252	232	344	3
3/31/2026	1,451	196	202	281	6
3/31/2025	1,374	158	125	201	7
3/31/2024	1,295	126	133	218	7
12/30/2023	1,270	127	129	197	N/A
9/30/2023	1,239	128	199	262	N/A
7/1/2023	1,219	137	176	250	N/A
4/1/2023	1,169	115	163	273	N/A
12/31/2022	1,129	96	128	261	N/A
10/1/2022	1,084	86	116	260	N/A
7/2/2022	1,026	68	88	216	N/A
4/2/2022	993	43	76	172	N/A
1/1/2022	953	23	33	106	N/A
10/2/2021	934	31	54	110	N/A
7/3/2021	903	64	52	95	N/A
4/3/2021	870	79	72	109	N/A
12/26/2020	884	108	118	154	N/A
9/26/2020	903	106	120	167	N/A
6/27/2020	946	96	119	167	N/A
3/28/2020	988	77	109	158	N/A
12/28/2019	999	80	81	132	N/A
9/28/2019	988	68	51	111	N/A
6/29/2019	977	49	39	139	N/A
3/30/2019	968	55	40	159	N/A
12/29/2018	952	46	72	196	N/A
9/29/2018	939	21	82	204	N/A
6/30/2018	922	23	116	205	N/A
3/31/2018	904	46	146	220	N/A
12/30/2017	898	-17	126	197	N/A
9/30/2017	892	4	N/A	187	N/A
7/1/2017	887	4	N/A	167	N/A
4/1/2017	886	-26	N/A	160	N/A
12/31/2016	900	16	N/A	178	N/A
10/1/2016	906	-59	N/A	155	N/A
7/2/2016	905	-66	N/A	143	N/A
4/2/2016	909	-56	N/A	122	N/A
12/26/2015	893	-50	N/A	124	N/A
9/26/2015	891	26	N/A	119	N/A
6/27/2015	899	20	N/A	123	N/A
3/28/2015	910	17	N/A	127	N/A
12/27/2014	925	30	N/A	123	N/A
9/27/2014	935	30	N/A	142	N/A
6/28/2014	943	39	N/A	140	N/A
3/29/2014	939	35	N/A	140	N/A
12/28/2013	947	38	N/A	116	N/A
9/28/2013	953	31	N/A	94	N/A
6/29/2013	935	21	N/A	98	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (21.1% al año) de HAE es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que los beneficios (21.1% al año) de HAE crezcan más rápidamente que el mercado US (14.7% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de HAE crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (6.8% al año) de HAE crezcan más despacio que el mercado de US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 6.8% al año) de HAE crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de HAE sea baja dentro de 3 años (19.1%).

Haemonetics Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Haemonetics Corporation Updates Revenue Guidance for the Fiscal Year 2024

Haemonetics Corporation Revises Revenue Guidance for the Fiscal Year 2024

Price target increased by 8.3% to US$109

Consensus EPS estimates increase by 25%

Haemonetics Corporation Provides Revenue Guidance for the Fiscal Year 2024

Haemonetics Corporation Revises Earnings Guidance for the Year 2023

Recent updates

Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?

Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion

Haemonetics Corporation to Report Q4, 2024 Results on May 09, 2024

Haemonetics Corporation Receives FDA Clearance for New TEG®? 6s Global Hemostasis - HN Cartridge

Haemonetics Corporation (NYSE:HAE) completed the acquisition of Advanced Cooling Therapy, Inc.

Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate

Haemonetics Corporation: Improved Performance, Another Bolt-On Deal

Haemonetics Corporation (NYSE:HAE) has entered into a definitive agreement to acquire Advanced Cooling Therapy, Inc. for $160 million.

The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Haemonetics Corporation Updates Revenue Guidance for the Fiscal Year 2024

Haemonetics Corporation to Report Q3, 2024 Results on Feb 08, 2024

The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).

Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).

Haemonetics: Solid Performance Of This Blood Play

Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today

Haemonetics Corporation Revises Revenue Guidance for the Fiscal Year 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Haemonetics (NYSE:HAE) A Risky Investment?

Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment

Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for CAD 345 million.

Haemonetics Corporation to Report Q2, 2024 Results on Nov 02, 2023

Independent Director notifies of intention to sell stock

Price target increased by 8.3% to US$109

Haemonetics' Fiscal Q1 2024: Blood, Sweat, And Stellar Gains

Haemonetics Corporation Elects Diane M. Bryant to Its Board of Directors

Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued

Insider notifies of intention to sell stock

Haemonetics Corporation to Report Q1, 2024 Results on Aug 08, 2023

Haemonetics Corporation to Report Q1, 2024 Results on Aug 08, 2023

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

CEO, President & Director exercised options and sold US$6.6m worth of stock

Haemonetics Corporation Receives FDA Clearance for Enhancements to NexSys PCS(R) Plasma Collection System

Haemonetics Corporation, Annual General Meeting, Aug 04, 2023

Executive VP & CTO recently sold US$192k worth of stock

Consensus EPS estimates increase by 25%

Haemonetics Corporation Provides Revenue Guidance for the Fiscal Year 2024

Full year 2023 earnings released: EPS: US$2.27 (vs US$0.85 in FY 2022)

Insufficient new directors

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?

Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer

Haemonetics Corporation Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Haemonetics: Earnings Rate Of Change Justifies High Multiples

Insider notifies of intention to sell stock

Investor sentiment improved over the past week

Haemonetics Corporation to Report Q3, 2023 Results on Feb 07, 2023

We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?

Price target increased to US$95.29

Price target increased to US$93.57

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Haemonetics Corporation Updates Revenue Guidance for the Year 2023

Haemonetics Q2 2023 Earnings Preview

Haemonetics Corporation Appoints Maryanne Farris as Principal Accounting Officer

Now 20% undervalued

Haemonetics Corporation to Report Q2, 2023 Results on Nov 07, 2022

Haemonetics Appoints Roy Galvin as President, Global Plasma and Blood Center

Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

Executive VP notifies of intention to sell stock

Haemonetics: Plasma Thesis Continues To Play Out, Reiterate Buy

Haemonetics reaches new 52-week high; shares up 41% YTD

Independent Director recently sold US$591k worth of stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Haemonetics Corporation (NYSE:HAE) announces an Equity Buyback for $300 million worth of its shares.